Candidates: Linebacker and Equivir

Type: Unspecified compounds with the potential to bind Angiotensin converting enzyme 2 (ACE2) and block SARS-CoV-2 entry into cells. Equivir is designed to work by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells, following deployment in a manner similar to a vitamin. Linebacker was created to mirror the Panacea Project, a U.S. Defense Advanced Research Projects Agency (DARPA) program created to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker is under continuing research against COVID-19, having showed efficacy against SARS and MERS in previous lab testing.

Status: Impact BioMedical’s Equivir and Linebacker showed in-vitro success as a treatment, as well as a prophylactic protecting the cells from infection by the virus, according to a July 9 announcement by a company in the process of acquiring Impact, Document Security Systems (DSS). Impact published results from in-vitro testing with Equivir and Linebacker, as well as 3F Biofragrance, against COVID-19 in independent laboratory testing.

The in vitro results, Impact said, confirmed predictions of advanced computational molecular docking in which Equivir and Linebacker bound with a high affinity to the COVID-19 helicase and protease. Equivir and Linebacker also caused “transformational” change in the host ACE-2 receptor, Impact said, interfering with the virus’ ability to interact and infect the host cell. In addition, 3F Biofragrance was successful as a surface disinfectant, killing the virus in concentrations as low as 1/5000 after 15 seconds in the invitro testing.

DSS said in March it agreed to acquire Impact for $50 million in common stock and convertible preferred stock. At the time, Impact said, its suite of antiviral and medical technologies was valued at $382 million by Destum Partners. Impact received a much higher valuation of $933 million in May from a different, undisclosed independent valuation firm, reflecting numerous additional disease applications of the suite of antiviral and medical technologies.

Also in March, Global BioMedical’s parent company Singapore eDevelopment (SeD) said that Impact and scientific research partner GRDG Sciences conducted molecular docking studies using advanced computational models showing that its Linebacker and Equivir compounds successfully inhibited infection by SARS-CoV-2. The compounds were to undergo testing after they were shown to block 3 integral viral mechanisms for SARS-CoV-2 replication and infection: the viral spike interaction point, helicase, and protease. SeD’s CEO and largest shareholder is Heng Fai Ambrose Chan, who is also Chairman and largest shareholder of DSS.

COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:


Previous articleMoleculin Biotech – WP1122
Next articleTulane University